Sorriso Pharmaceuticals is a Salt Lake City, UT–based biotechnology company led by president and CEO Ciara Kennedy that is advancing disease-modifying antibodies for inflammatory diseases including Crohn’s disease and ulcerative colitis. Its platform generates potent antibodies that can be delivered orally and are designed to maintain activity throughout the intestinal system. The lead program, SOR102, is in development for inflammatory bowel disease and simultaneously inhibits TNFα and IL-23, two clinically validated drivers of IBD. The company’s approach seeks to combine the clinical impact of injectable antibody therapeutics with the benefits of oral administration, producing targeted activity, negligible systemic exposure, and minimal immunogenicity. Sorriso intends to use the financing to advance its pipeline of novel oral antibodies to address unmet needs in immune-mediated diseases. The company recently closed a $31M Series A financing to fund those efforts.

Total raised

$31M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2021